Abstract: Method and pharmaceutical compositions for treating or limiting the occurrence of viral infections by administering a therapeutically effective amount of a pharmaceutical composition that targets the ACE2 active site. The pharmaceutical compositions include those of Formula (I), Formula (II), Formula (III), including Formulas (IIIa) and (IIIb), and the viral infections including but not limited to respiratory viruses and disease conditions and syndromes that are associated with the viral infections.

Abstract: A therapeutic compound has a modified phenolic compound of the general formula (I) wherein at least one of R, R1, R2, R3, and R4 is an electrophilic group chosen from halogen, aldehyde, haloalkane, alkene, butyryl, flurophenol, sulfonamide, flurophenol sulfoxide and the remaining R, R1, R2, R3, and R4 is are each independently hydrogen, a hydroxyl group, an alkoxy group, a rutinosyl group, a carboxyl group, chromone, benzopyran, a rhamnosyl group, a substituted alkoxy group or a substituted acyloxy group wherein the substituent is chosen from hydroxyl, alkoxy, aryloxy, phenyl, halogen, and amido group. The compound can be used in a therapeutic treatment of inflammatory related diseases and condition.

Abstract: A therapeutic compound has a modified phenolic compound of the general formula (I) wherein at least one of R, R1, R2, R3, and R4 is an electrophilic group chosen from halogen, aldehyde, haloalkane, alkene, butyryl, flurophenol, sulfonamide, flurophenol sulfoxide and the remaining R, R1, R2, R3, and R4 is are each independently hydrogen, a hydroxyl group, an alkoxy group, a rutinosyl group, a carboxyl group, chromone, benzopyran, a rhamnosyl group, a substituted alkoxy group or a substituted acyloxy group wherein the substituent is chosen from hydroxyl, alkoxy, aryloxy, phenyl, halogen, and amido group. The compound can be used in a therapeutic treatment of inflammatory related diseases and condition.

Abstract: A therapeutic compound has a modified phenolic compound of the general formula (I) wherein at least one of R, R1, R2, R3, and R4 is an electrophilic group chosen from halogen, aldehyde, haloalkane, alkene, butyryl, flurophenol, sulfonamide, flurophenol sulfoxide and the remaining R, R1, R2, R3, and R4 is are each independently hydrogen, a hydroxyl group, an alkoxy group, a rutinosyl group, a carboxyl group, chromone, benzopyran, a rhamnosyl group, a substituted alkoxy group or a substituted acyloxy group wherein the substituent is chosen from hydroxyl, alkoxy, aryloxy, phenyl, halogen, and amido group. The compound can be used in a therapeutic treatment of inflammatory related diseases and condition.

Abstract: A therapeutic compound has a modified phenolic compound of the general formula (I) wherein at least one of R, R1, R2, R3, and R4 is an electrophilic group chosen from halogen, aldehyde, haloalkane, alkene, butyryl, flurophenol, sulfonamide, flurophenol sulfoxide and the remaining R, R1, R2, R3, and R4 is are each independently hydrogen, a hydroxyl group, an alkoxy group, a rutinosyl group, a carboxyl group, chromone, benzopyran, a rhamnosyl group, a substituted alkoxy group or a substituted acyloxy group wherein the substituent is chosen from hydroxyl, alkoxy, aryloxy, phenyl, halogen, and amido group. The compound can be used in a therapeutic treatment of inflammatory related diseases and condition.

Abstract: A composition and method for treating diabetes and metabolic disorders, and for achieving weight loss in a subject comprising a combination of naturally occurring compounds is provided.

Abstract: A composition and method for treating diabetes and metabolic disorders, and for achieving weight loss in a subject comprising a combination of naturally occurring compounds is provided.

Abstract: A composition and method for treating diabetes and metabolic disorders, and for achieving weight loss in a subject comprising a combination of naturally occurring compounds is provided.

Abstract: The composition for treating neurological disorders such as Alzheimer's Disease is provided. The composition includes a modified flavonoid compound having enhanced binding affinity to metabolic modulating enzymes. The composition is effective to down-regulate beta- and gamma-secretase and up-regulate alpha secretase, which results in a reduction in amyloid proteins.

Abstract: A composition and method for treating diabetes and metabolic disorders, and for achieving weight loss in a subject comprising a combination of naturally occurring compounds is provided.

Abstract: A composition and method for treating diabetes and metabolic disorders, and for achieving weight loss in a subject comprising a combination of naturally occurring compounds is provided.

Abstract: The composition for treating neurological disorders such as Alzheimer's Disease is provided. The composition includes a modified flavonoid compound having enhanced binding affinity to metabolic modulating enzymes. The composition is effective to down-regulate beta- and gamma-secretase and up-regulate alpha secretase, which results in a reduction in amyloid proteins.

Abstract: A composition and method for treating diabetes and metabolic disorders, and for achieving weight loss in a subject comprising a combination of naturally occurring compounds is provided.